Get ready for the event of the year in cardiovascular science! The American Heart Association (AHA) will host its highly anticipated 2024 Scientific Sessions from November 16 to 18 in the vibrant city of Chicago, promising to be a treasure trove of cutting-edge research and clinical knowledge.

This annual gathering showcases the latest advancements in cardiovascular medicine, featuring pivotal studies, guidelines for clinical practice, and presentations from early innovators in the field. As always, this year’s sessions will include late-breaking science that could redefine how we understand and treat heart conditions.

Key Highlights to Look Forward To:

1. Breakthroughs in Heart Failure Treatments:

On Saturday, the much-anticipated findings from the SUMMIT trial (NCT04847557) will be presented by Dr. Milton Packer. This trial investigates the efficacy of tirzepatide in patients with heart failure and obesity. Remarkably, earlier data indicated that patients treated with tirzepatide experienced a 38% reduction in heart failure outcomes compared to those receiving a placebo. Dr. Packer will delve into the implications of these groundbreaking results and their potential to transform treatment paradigms.

2. Addressing Medication Adherence Challenges:

Rachel Chandra, PharmD, MPH, FASHP, will shed light on the crucial topic of statin adherence in patients with Atherosclerotic Cardiovascular Disease (ASCVD). Despite existing guidelines, less than 50% of patients continue their statin therapy after one year, a figure that drops below 30% after two years. Such statistics underscore the vital role pharmacists can play in enhancing adherence and improving patient outcomes.

3. Decoding GLP-1 Receptor Agonists:

On Sunday, a session dedicated to glucagon-like peptide-1 (GLP-1) receptor agonists will explore their multifaceted role in cardiovascular therapy. Presenters will clarify the physiological effects of these agents and share trial evidence that will guide clinicians on effective integration of these medications into patient care, particularly addressing challenges such as cost and accessibility.

4. The Impact of Historical Injustices on Health:

Dr. Rebekah Walker will present her findings on the correlation between redlining—a practice of systemic discrimination—and the prevalence of cardiometabolic diseases. Her research emphasizes how lack of access to healthy food contributes to higher rates of diabetes, hypertension, and obesity in affected neighborhoods, driving home the importance of pharmacies as vital health resources in these communities.

5. Innovations in Bleeding Risk Assessment:

Lastly, in-depth insights from Dr. Christian Ruff regarding the AZALEA-TIMI 71 trial will be revealed. This trial evaluates the safety of the factor XI inhibitor abelacimab compared to rivaroxaban, particularly in patients undergoing antiplatelet therapy. As this phase 2b study unfolds, the results promise to advance our understanding of bleeding risks associated with these treatments.

As the AHA 2024 Scientific Sessions unfold, stay updated through exclusive insights and interviews available on Pharmacy Times’ website and social media channels. This is an event that promises to reshape the future of cardiovascular care—don't miss it!